GlaxoSmithKline bails on Basilea’s eczema drug, nixing a $72M payout

Damian Garde GlaxoSmithKline has abandoned its plot to win FDA approval for an eczema treatment from Basilea Pharmaceutica, ending a project that could have paid its partner about $ ...

GlaxoSmithKline scientists accused of stealing drug R&D secrets for China scheme

John Carroll Yu Xue had a hard-earned reputation as a top chemist while she was working for GlaxoSmithKline in its Upper Merion, PA, facility. But Yu Xue–better known as Joyce–was ...

GlaxoSmithKline and Five Prime ditch lung cancer ambitions as rivals pile in

Damian Garde Partners GlaxoSmithKline and Five Prime Therapeutics are abandoning their hopes of developing an early-stage drug for lung cancer, pivoting to mesothelioma as the landscape ...

GlaxoSmithKline bags an FDA OK for its asthma drug with eyes on a respiratory turnaround

Damian Garde GlaxoSmithKline won FDA approval for an antibody designed to treat severe asthma, leading a pack of drugmakers at work on similar therapies as it seeks to bolster its respiratory ...

Isis and GlaxoSmithKline eye Phase III with a rare disease drug

Damian Garde GlaxoSmithKline and partner Isis Pharmaceuticals are plotting a pivotal trial in the rare TTR amyloid cardiomyopathy, an inherited disease that impairs the heart muscle. FierceBiotech ...

UPDATED: On the ropes, GlaxoSmithKline admits to another PhIII debacle

John Carroll GlaxoSmithKline, which recruited more than 16,000 patients in a monumental postapproval effort to distinguish Breo Ellipta by improving the mortality rates of high-risk ...

GlaxoSmithKline and Purdue look to Apple’s ResearchKit for R&D

Damian Garde ResearchKit, the technology Apple promises will transform the world's hundreds of millions of iPhones into handheld gatherers of clinical data, could become a viable ...

Spurned by AstraZeneca, is Pfizer out for GlaxoSmithKline?

Damian Garde The latest market chatter is that Pfizer, rebuffed in its quest to acquire AstraZeneca last year, is taking a hard look at GlaxoSmithKline, and one analyst says it might ...

UPDATED: GlaxoSmithKline to create new vaccines hub, uprooting R&D groups in Cambridge, Philly

John Carroll GlaxoSmithKline is setting up a global vaccines hub in Rockville, MD, in the wake of its big asset swap with Novartis. And the move will force hundreds of staffers in Cambridge, ...

GlaxoSmithKline tags 180 sales-and-admin jobs for cutting in NC

Carly Helfand Last year, GlaxoSmithKline announced plans to slim down its Research Triangle Park, NC-based operations, chopping 900 jobs. Now, it's telling state officials that ...

GlaxoSmithKline CEO: Chin up, investors. Dividend’s safe, and Novartis deal awaits

Carly Helfand GlaxoSmithKline's shareholders may be expecting less-than-stellar sales next year as generics take their toll on respiratory behemoth Advair. But they still have plenty ...

GlaxoSmithKline heads to the FDA with its next big respiratory bet

Damian Garde GlaxoSmithKline is racing to be the first on the market with a new approach to treating severe asthma, filing U.S. and European applications for the injectable mepolizumab ...
Page 1 of 712345...Last »
© 2017 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS